Flash FinanceUS
Market closed S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · West Pharmaceutical Services (WST)

West Pharmaceutical Services Reports Q3 2026 Results and Raises Full-Year Guidance

Positive Impact 4 of 5 guidance

West Pharmaceutical Services reported third-quarter 2026 net sales of $874.5 million and diluted earnings per share of $3.02, reflecting growth compared to the prior-year period. Driven by strong execution in its Proprietary Products segment, the company raised its full-year net sales and adjusted-diluted EPS guidance ranges.

Key points

  • Q3 2026 net sales reached $874.5 million, up 8.7% year-over-year, with diluted EPS of $3.02.
  • Full-year 2026 net sales guidance was increased to a range of $3.41 billion to $3.42 billion.
  • Full-year 2026 adjusted-diluted EPS guidance was raised to a range of $9.38 to $9.48.
  • The company repurchased $231 million of stock in the third quarter, bringing year-to-date repurchases to $685 million.

The filing

CompanyWest Pharmaceutical Services (WST)
Form8-K, current report
Filed with the SECOct 29, 2026, 7:06 AM ET
Accession number0000105770-26-000118

Items reported: 2.02 Results of Operations7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Oct 30, 2026, 8:17 AM ET, from this filing only.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.